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SUMMARY 
 Neurodevelopmental disabilities are a group of chronic heterogeneous disorders, 
which include clinically distinct, chronic disorders whose essential and unifying feature 
is a disturbance in developmental progress in one or more developmental domains.  
Objectives 
 The aims of this study were to estimate the share of neurodevelopmental 
disabilities among patients referred to a Paediatric Neurology Service in a region in 
Hungary and study the spectrum of disability subtypes in this cohort. Our further 
objective was to search for the aetiological factors leading to neurodevelopmental 
disability, estimate the degree of intellectual disability (mental retardation) in the 
various subgroups and compare our results with figures in the literature. Setting up a 
manageable database for further research and public health services was also intended. 
Patients and methods 
 A retrospective survey of patients with neurodevelopmental disabilities referred 
to the Paediatric Neurology Service at the Department of Paediatrics, Division B, 
University of Szeged, Hungary between 1 January 2006 and 31 December 2011 was 
performed. Detailed history was taken followed by physical and neurologic 
examinations and neuropsychological testing. Further investigations (imaging, 
metabolic screening, histopathology, cytogenetic, molecular cytogenetic tests, or 
mutation analysis of candidate genes) were directed by the history and examinations.  
Results 
 This study included 241 (131 boys, 110 girls) out of 1764 children (13.7%) 
referred to the Paediatric Neurology Service. Neurodevelopmental disability occurred 
without any known prenatal, perinatal, and/or neonatal averse events in 167 patients 
(69.3%), while known prenatal, perinatal, and/or neonatal adverse events were found in 
74 children (30.7%).  
Patients without adverse events were classified into the following subgroups: 
genetic syndromes with recognized aetiology (12.0%), global developmental 
delay/intellectual disability (mental retardation) in association with dysmorphic features 
not recognized as specific syndromes (9.5%), global developmental delay/intellectual 
disability (mental retardation) without recognized aetiology and dysmorphic features 
(18.7%), brain malformations (14.5%), inborn errors of metabolism (2.5%), 
leukoencephalopathies (1.7%), epileptic syndromes (1.7%), developmental (specific) 
language impairment (3.7%), and neuromuscular disorders 5.0%). Patients with adverse 
 5 
 
events comprised the following subgroups: cerebral palsy after preterm delivery 
(14.9%), after delivery at term (8.3%), and disability without cerebral palsy (7.5%). 
Overall the aetiology of the neurodevelopmental disabilities was identified in 
66.4% of the patients and well documented genetic diagnosis was found in 19.5%.  
Conclusions 
 Recognition of causes of neurodevelopmental disabilities helps starting adequate 
treatment, when feasible, and establishing a health maintenance plan and rehabilitation. 
It provides prediction of the outcome, helps in avoiding unnecessary diagnostic tests 
and contributes to the prevention of the disorder. Our database can be used for further 
studies on the genetic and environmental causes of neurodevelopmental disorders and it 
provides useful information for the health authorities on the special needs of children 
living with neurodevelopmental disabilities. 
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ÖSSZEFOGLALÁS 
 Az idegrendszeri funkciók fejlődése késlekedhet egy vagy több részterületen 
különböző súlyosságú fogyatékosságot okozva. A fogyatékosság hátterében különböző 
klinikailag diagnosztizálható kórképek állnak, amelyek közös jellemzője, hogy a beteg 
motoros és/vagy szellemi fejlődése, beszédkészsége változó mértékben elmarad az 
életkori átlagtól.  
Célkitűzések 
 Az egy vagy több részterületen fogyatékos gyermekek arányát kívántuk 
tanulmányozni Magyarország egyik régiójának gyermekneurológiai szakrendelésére 
beutalt betegek között, továbbá meg kívántuk állapítani a fogyatékosság fő típusait. 
Célul tűztük ki a fogyatékosság okának kiderítését és szellemi fogyatékosság esetén 
vizsgálni kívántuk annak súlyosságát a különböző diagnosztikus csoportokban. Célunk 
volt, hogy eredményeinket összehasonlítsuk a nemzetközi szakirodalomban talált 
adatokkal. Egy adatbázist kívántunk létesíteni, amely alkalmazható további kutatási 
célra és hasznos lehet az egészségügyi szolgálat számára is. 
Betegek és módszerek 
 A Szegedi Tudományegyetem Gyermekgyógyászati Klinika B Részlegének 
neurológiai szolgálatán 2006. január 1. és 2011. december 31. között megjelent 
gyermekek körében végeztük a vizsgálatainkat. Az anamnézis részletes felvételére, 
fizikális, neurológiai és neuropszichológiai vizsgálatra került sor a gondozás során. 
További vizsgálatok (képalkotó módszerek alkalmazása, anyagcsere vizsgálat, 
szövettan, citogenetikai, molekuláris citogenetikai tesztek, mutáció analízis) az 
anamnézis és a klinikai vizsgálatok eredményétől függően történtek.  
Eredmények 
 Hat év alatt 1764 beteget vizsgáltunk, ebből 241 gyermeket (13.7%, 131 fiú, 110 
leány) vettünk be a tanulmányunkba. Fogyatékosságot találtunk valamilyen praenatalis, 
perinatalis és/vagy újszülöttkori ismert rizikótényező nélkül 167 betegnél (69.3%), míg 
a fogyatékosság hátterében rizikó faktornak tartható praenatalis, perinatalis és/vagy 
újszülöttkori esemény állt 74 betegnél (30.7%).  
 Az azonosítható rizikófaktor nélkül kialakult fogyatékossággal élő gyermekeket 
a következő alcsoportokba soroltuk be: ismert etiológiájú genetikai szindrómák 
(12.0%), dysmorphismussal társuló, de szindromológiailag be nem sorolható globálisan 
késlekedő fejlődés/szellemi fogyatékosság (9.5%), ismeretlen etiológiájú globálisan 
késlekedő fejlődés/szellemi fogyatékosság dysmorphismus nélkül (18.7%), agyi 
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fejlődési rendellenességek (14.5%), veleszületett anyagcsere betegségek (2.5%), a 
fehérállomány betegségei (1.7%), epilepsziás szindrómák (1.7%), megkésett 
beszédfejlődés mint részfunkció-zavar (3.7%) és neuromuscularis betegségek (5.0%). 
Az ismert rizikótényező következtében kialakult fogyatékossággal élő betegek körében 
3 alcsoportot különítettünk el: cerebralis paresis koraszülöttekben (14.9%), cerebralis 
paresis érett újszülöttekben (8.3%) és különböző típusú fogyatékosság cerebralis paresis 
nélkül (7.5%). 
 Az összes beteget tekintve a fogyatékosság oka a gyermekek 66.4%-ában derült 
ki, genetikai okot pedig 19.5%-ban találtunk. 
Következtetések 
  Az idegrendszeri fejődés egy vagy több részterületét érintő fogyatékosság oka 
az esetek több mint felében diagnosztizálható. Az etiológia kiderítése alapvetően fontos 
annak érdekében, hogy az újabb kutatások által feltárt terápiás lehetőségeket 
alkalmazhassuk. A megfelelő gondozás és az egyénre szabott rehabilitációs program 
kidolgozása is megkívánja az etiológia ismeretét. A specifikus kórokok kiderítése révén 
elkerülhetőek a beteget terhelő szükségtelen vizsgálatok, prognosztizálható a kimenetel 
és számos esetben megelőzhető a kórkép ismétlődése egy családban. 
 Adatbázisunk hozzájárul ahhoz, hogy az új tudományos eredményeket megfelelő 
időben alkalmazni tudjuk betegeinknél és segíti az egészségügyi ellátórendszert a 
fogyatékosok speciális igényeinek felmérésében. 
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INTRODUCTION 
 Neurodevelopmental disabilities are a group of chronic heterogeneous disorders, 
which include clinically distinct, chronic disorders whose essential and unifying feature 
is a documented disturbance in developmental progress, either quantitative or 
qualitative, or both, compared with established norms in one or more recognized 
developmental domains.1 These domains traditionally include: motor (gross or fine), 
speech/language, cognition, personal/social, and activities of daily living.1-3 
 Neurodevelopmental disabilities have been divided into subtypes.1,2 These 
subtypes are essentially “symptom complexes” rather than specific disorders or diseases 
and they share marked heterogeneity within each subtype.1,2 Based on previous 
conceptualization global developmental delay, mental retardation/intellectual disability, 
cerebral palsy, gross motor delay including mostly the neuromuscular disorders, 
developmental language impairment as a single domain developmental delay and 
autistic spectrum disorders can be regarded as the main categories of 
neurodevelopmental disabilities.1-3  
 Global developmental delay applies to children less than 5 years and it is defined 
as a significant delay in two or more developmental domains.4,5 Global developmental 
delay may be an early marker of what is termed mental retardation, which is typically 
diagnosable in the child older than 5 years of age.5 The present consensus definition of 
“mental retardation,” put forward by the American Association on Mental Retardation 
(now the American Association on Intellectual and Developmental Disabilities) in 2002, 
describes this entity as “a disability characterized by significant limitation both in 
intellectual functioning and adaptive behaviour as expressed in conceptual, social, and 
practical adaptive skills”.5 Intellectual disability is the currently preferred term for 
mental retardation.6,7 
 Cerebral palsy describes a group of permanent disorders of the development of 
movement and posture, causing activity limitation, that are attributed to non-progressive 
disturbances that occurred in the developing foetal or infant brain.8 Neurodegenerative, 
neurometabolic, and neoplastic processes do not underlie cerebral palsy; however some 
controversy exists regarding the inclusion of potentially progressive vascular (i.e. 
moyamoya) or traumatic (i.e. shaken baby syndrome) aetiologies under this term.8 
Single domain neurodevelopmental delay in the motor or language area has been 
suggested by Shevell and coworkers.1,9 Indeed acquisitions of motor skills is the main 
area of delay in diseases of the motor unit, however the cognition can also be affected in 
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several muscle disorders suggesting an overlap between different categories of 
neurodevelopmental disabilities. Developmental (specific) language impairment refers 
to a significant delay in speech and language skills with normal performance in other 
developmental domains or activities of daily living.1,9,10  
 In addition to the main categories of neurodevelopmental disabilities other 
subtypes, such as isolated hearing loss, isolated visual impairment, autism, specific 
learning disability, attention-deficit-hyperactivity disorder, developmental co-ordination 
disorder (“clumsy” children) etc. also occur in the setting of the neurodevelopmental 
disabilities,1,3 however these conditions will not be dealt with in this study . 
 The role of the paediatric neurologist/neuropsychologist when assessing these 
patients is several-fold: to verify that neurodevelopmental disability does indeed exist, 
carefully search for an underlying aetiology, provide access and referral to adequate 
therapeutic and rehabilitation resources, and offer prognostication.11-14  
 Several syndromes and disorders with neurodevelopmental disability (e.g. 
genetic syndromes, inborn errors of metabolism, or certain types of muscle diseases) are 
rare diseases (orphan diseases).15,16 Any disease affecting less than 1 in 2000, i.e. 5 
people in 10 000 is considered rare in the European Union.16 Living with a rare disease 
raises several special difficulties.16 Studies by the European Organization for Rare 
Diseases (EURORDIS) revealed that there is a lack of quality information on and 
scientific knowledge of these diseases, therefore the correct diagnosis is delayed and the 
patients lack appropriate quality healthcare .16  
    Several population- and cohort-based studies and reviews on the various features 
of global developmental delay and intellectual disability/mental retardation have been 
published earlier,17-25 and efforts have been made for the characterization of single 
domain disorders as well.9 Based on the progress in paediatric neurosciences, 
acknowledging the merits of previous classification schemes, a more refined 
classification of neurodevelopmental disabilities, including more distinct subtypes of 
disorders, seems to be required. Our aim was to establish a comprehensive classification 
scheme, rather dissimilar to the previous ones, in order to characterize the spectrum of 
neurodevelopmental disabilities and demonstrate the clinical utility of this classification 
scheme as an organizing framework for clinical investigations. Aetiology of the 
disabilities has been searched for and the degree of intellectual disability in each 
diagnostic subtype has also been assessed. 
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OBJECTIVES 
The following objectives were targeted by our study: 
1./ To perform a retrospective survey of children with neurodevelopmental disabilities 
in a cohort of patients referred to a paediatric neurology service at a university hospital 
in South-Eastern Hungary in order 
- to estimate the share of neurodevelopmental disabilities among all patients 
 referred to the service 
- to establish the spectrum of neurodevelopmental disability subtypes in this 
 cohort of patients   
 - to search for aetiological factors leading to neurodevelopmental disability 
- to estimate the incidence of different severity degrees of intellectual disability 
(mental retardation) among patients with neurodevelopmental disabilities 
 - to compare our results with data published by other cohort studies 
2./ To establish and manage a regional database for the following purposes: 
 - to search for environmental factors beyond obstetrical complications 
responsible for neurodevelopmental disabilities  
- to encourage genetic studies to promote preimplantation and prenatal diagnosis  
in subsequent pregnancies  
 - to draw the attention of decision-makers to the special needs of children living 
 with neurodevelopmental disabilities 
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PATIENTS AND METHODS 
   A retrospective survey of patients with neurodevelopmental disabilities referred 
to the Paediatric Neurology Service (outpatient and inpatient) at the Department of 
Paediatrics, Division B, University of Szeged, Hungary between 1 January 2006 and 31 
December 2011 was carried out.  
 An algorithm was designed for the evaluation of patients with 
neurodevelopmental disabilities. This scheme for diagnostic work-up followed the 
recommendations by the Quality Standards Subcommittee of the American Academy of 
Neurology and The Practice Committee of the Child Neurology Society4, van 
Karnebeek and co-workers20 and Wilska and Kaski26 (Table 1). Standard assessment 
included clinical history of the antenatal, perinatal, neonatal, and postnatal period. 
Developmental milestones and behavioural phenotype were also assessed. Physical and 
neurological examinations were performed with attention even to soft neurological 
signs. Hearing was always tested and neuro-ophthalmologic consultation was also an 
integral part of the physical examination (Table 1). 
Special attention has been paid to the presence of malformations and/or 
dysmorphic features. Data on malformations of any organ system(s) were retrieved 
from the previous medical records. Physical anomalies detectable by surface 
examination were described as recommended in the literature.27-35  
 Developmental and cognitive evaluations were performed by the Hungarian 
adaptations of the revised Brunet-Lézine36 (below 3 years of age), Stanford-Binet37 
(Budapest Binet, between the ages of 3 and 6 years) tests,  WISC-IV (Wechsler 
Intelligence Scale for Children – Fourth Edition, between the ages of 6 and 16 years),38 
and Woodcock Johnson III Tests of Achievement (above 16 years of age).39 In cases 
where cognitive functioning was extremely reduced and/or behaviour was substantially 
disturbed, not allowing the administration of formal test, DQ/IQ scale was assessed 
indirectly based upon clinical descriptions of the child’s functioning. 
 Developmental delay and intellectual disability (mental retardation) was 
classified according to the DSM-IV-TR40 by measure of DQ or IQ as severe to profound 
(DQ/IQ level below 35-40), moderate (DQ/IQ level 35-40 to 50-55), mild (DQ/IQ level 
50-55 to approximately 70), and borderline (DQ/IQ 70-85). Children with severe and 
profound developmental delay and intellectual disability (mental retardation) were 
grouped together in a single category. 
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Neuropsychological assessment was carried out partly by our own clinical 
testing, partly by personal or telephone interviews. There is a national network of 
Committees for the Assessment of Learning Abilities and Rehabilitation in Hungary. 
Infants or children with suspected global developmental delay, or intellectual disability 
(mental retardation) are entitled to be tested and advised by these committees. Special 
institutions for children with visual (National Committee for the Assessment of Vision 
Abilities and Rehabilitation), or hearing impairments (National Committee for the 
Assessment of Hearing Abilities and Rehabilitation), speech (National Committee for 
Speech Assessment and Rehabilitation), or movement disorders (National Committee 
for the Assessment of Movement and Rehabilitation) also provide assessment in 
Hungary. DQ/IQ scores were retrieved by personal or telephone interviews from the 
reports issued by these committees for those patients with neurodevelopmental 
disabilities whose parents were reluctant to expose their children to another test at our 
department.  
 Cerebral palsy and its complications were diagnosed by neurologic examination  
and classified as spastic diplegia, quadriplegia, hemiplegia, extrapyramidal, and 
hypotonic cerebral palsy.41  
Brain imaging (ultrasound, CT, and MRI), EEG, tests for intrauterine infection 
and screening for inborn errors of metabolism were carried out by conventional 
protocols. Muscle biopsy specimen was taken from patients with suspected congenital 
myopathies. Chromosomal analysis with G-band technique was carried out for patients 
with intellectual disability (mental retardation), dysmorphic features, or multiple 
anomalies. FMR1 gene test was performed for children with intellectual disability 
(mental retardation) if no other etiology was evident. Fluorescence in situ hybridization 
(FISH) with specific probes or mutation analysis of putative genes were requested for 
the confirmation of particular diagnoses suspected on the basis of clinical, imaging, 
laboratory, biochemical, or histopathological features. For a few patients with 
intellectual disability (mental retardation) and dysmorphic features subtelomeric FISH, 
or array comparative genome hybridization (aCGH) were also carried out.  
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Table 1. Algorithm for the aetiological diagnosis of neurodevelopmental disabilities 
              (Modified from Shevell et al.4, van Karnebeek et al.20 and Wilska and Kaski26) 
 
 
DETAILED HISTORY 
 
Antenatal, perinatal, neonatal, medical, developmental, psycho-social, environmental, and family history 
 
 
EXAMINATIONS 
 
Physical and neurologic examination 
(Special attention to dysmorphic features /major/minor malformations) 
Neuropsychological testing 
Consultations: audiologist /ophthalmologist  
 
 
ARE THERE FEATURES SUGGESTING A SPECIFIC DIAGNOSIS? 
 
A. Are there historical or physical findings (e.g. dysmorphic features) to suggest specific syndromes (e.g. 
     Down, Fragile X, Rett syndrome, etc.), or any other genetic disorders? 
B. Are there historical data (e.g. intrauterine infection, intrapartum asphyxia, very low birth weight, etc.), 
     physical findings (e.g. cerebral palsy, focal findings, microcephaly, etc.), or seizures to suggest CNS 
     injury/malformation? 
C. Are there historical data (e.g. weak foetal movements, etc.), or signs (e.g. hypotonia, weakness, areflexia) to 
     suggest neuromuscular disorders?  
D. Is there a known metabolic disorder in the family, history of episodic decompensation, loss or regression of 
     developmental milestones, history of  parental consanguinity, prior unexplained loss of a child, or multiple 
     miscarriages? 
 
 
YES 
 
 
NO 
 
A 
 
 
B 
 
C 
 
D 
MRI 
Bone x-ray 
Cytogenetic and molecular 
cytogenetic (subtelomeric 
FISH, microarray-based 
cytogenetic technology) 
tests  
FMR1 and/or MeCP2 gene 
tests 
Metabolic testing* 
 
Specific tests for 
that disorder 
 
Cytogenetic and 
molecular 
cytogenetic 
(subtelomeric 
FISH, microarray-
based cytogenetic 
technology) tests  
Specific gene tests 
 
Bone X-ray 
 
Metabolic testing* 
 
 
MRI 
(CT) 
 
Tests for 
infections if 
appropriate   
Serum CK 
EMG, ENG 
Specific gene 
tests  
Muscle biopsy 
MRI 
EEG 
Bone X-ray 
Metabolic testing* 
Histopathology 
(lymphocytes, skin, 
conjunctiva, liver, bone 
marrow, peripheral 
nerve)  
Cytogenetic and 
molecular cytogenetic 
(subtelomeric FISH, 
microarray-based 
cytogenetic technology) 
tests  
Specific gene tests 
*Based on historical features, clinical, physical and/or imaging findings metabolic tests were requested if appropriate: 
plasma amino acids, carnitine esters, carnitine, uric acid, lactate, pyruvate, ammonia, very long chain fatty acids, 
phytanic acid, copper, ceruloplasmin, transferrin isoelectric focusing (for congenital defects of glycosylation), 
leukocyte lysosomal enzymes, urinary organic acids, mucopolysaccharides, sulphites, blood/urine screening for 
disorders of creatine metabolism, cerebrospinal fluid (CSF/blood ratio) glucose, lactate, pyruvate and amino acids 
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 Patients with traumatic brain injury and CNS infections beyond the neonatal 
period and children with CNS tumours were not included in this study because special 
services provide care for these patients in Hungary.  
 Chi-squared goodness-of-fit test for uniform distribution was used to determine 
whether any gender predominance existed within the diagnostic groups or any degree of 
intellectual disability prevailed within a diagnostic subtype. p≤0.05 was used for 
establishing statistical significance. Pearson residuals were used as a measure of 
deviance from the hypothesized uniform distribution.       
An informed consent to participate in this study was requested from the parents. 
This study was approved by the Ethics Committee of the Faculty of Medicine, 
University of Szeged (Szeged, Hungary).  
 The classification of neurodevelopmental disabilities in this study can be seen in 
Table 4.  
 15 
 
RESULTS 
Total number of 1764 patients was referred to the Paediatric Neurology Service 
at the Department of Paediatrics, Division B, University of Szeged between 1 January 
2006 and 31 December 2011. Neurodevelopmental disability was ascertained in 316 
patients (17.9%) and eventually 241 patients (13.7%) were included in this study. The 
mean age of these children was 7.2 ± 4.6 years (age range: 0.5-22 years) at the last 
follow up. There were 131 boys and 110 girls and the male/female ratio was 1.19, 
however the male preponderance was statistically not significant. The gender 
distribution in the subgroups of patients with different categories of 
neurodevelopmental disabilities is shown in Table 2. There was a trend of male 
predominance in the moderate, mild and borderline categories, while more girls were 
observed among patients with severe/profound global developmental delay/intellectual 
disability (Table 2). 
 The neuropsychological assessment was carried out in our institution for 74 
children (Brunet-Lézine test: 23, Budapest Binet: 33 and WISC-IV: 18) and the scores 
for cognitive abilities were obtained by interviews for 167 patients. The assessment 
methods applied in different categories of disabilities can be seen in Table 3.  
Neurodevelopmental disability occurred without known prenatal, perinatal, 
and/or neonatal adverse events in 167 patients (69.3%), while known prenatal, 
perinatal, and/or neonatal adverse events were responsible for the 
neurodevelopmental disability in 74 children (30.7%, Table 4).  
  
 
Table 2. Gender distribution in different subgroups of patients with neurodevelopmental disabilities 
     
 
 
 
Patient subgroups 
 
Gender distribution and ratios in different categories of global developmental delay/intellectual disability (mental retardation)+ 
  
SP+ MO+ MI+ BL+ NO# Total 
M F M/F 
ratio 
M F M/F 
ratio 
M F M/F 
ratio 
M F M/F 
ratio 
M F M/F 
ratio 
M F M/F 
ratio 
No adverse events                   
   Global developmental delay/intellectual disability 
   (mental retardation) 
                  
        Genetic syndromes with recognized aetiology 2 3 0.67 5 5 1.00 5 3 1.67 3 3 1.00 0 0 NR 15 14 1.07 
        Children with dysmorphic features not recognized as 
        specific syndromes 
8 7 1.14 3 0 NR 2 3 0.67 0 0 NR 0 0 NR 13 10 1.30 
        Children without recognized aetiology and dysmorphic 
        features 
8 13 0.62 6 1 6.00 8 5 1.60 1 3 0.33 0 0 NR 23 22 1.05 
        Brain malformations 11 10 1.10 2 2 1.00 2 3 0.67 3 1 3.0 0 1 NR 18 17 1.06 
        Inborn errors of metabolism 2 0 2.00 2 1 2.00 1 0 NR 0 0 NR 0 0 NR 5 1 5.00 
        Leukoencephalopathies 1 1 1.00 0 1 NR 1 0 NR 0 0 NR 0 0 NR 2 2 1.00 
        Epileptic syndromes 0 2 NR 0 0 NR 2 0 NR 0 0 NR 0 0 NR 2 2 1.00 
   Developmental (specific)  language impairment 0 0 NR 0 0 NR 0 0 NR 4 0 NR 5 0 NR  9* 0 NR 
   Neuromuscular disorders 1 0 NR 1 0 NR 3 0 NR 0 0 NR 2 5 0.40 7 5 1.40 
Adverse events (prenatal, perinatal, neonatal)                   
   Cerebral palsy after preterm delivery 8 7 1.14 1 1 1.00 3 1 3.00 6 2 3.00 2 5 0.40 20 16 1.25 
   Cerebral palsy after delivery at term 4 4 1.00 2 1 2.00 0 1 NR 1 1 1.00 3 3 1.00 10 10 1.00 
   Neurodevelopment disabilities without cerebral palsy 2 6 0.33 1 0 NR 3 5 0.60 1 0 NR 0 0 NR 7 11 0.64 
Total 47 53 0.89 23 12 1.92 30 21 1.43 19 10 1.90 12 14 0.86 131 110 1.19 
 M = male, F = female, +Degree of global developmental delay/intellectual disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, BL =  borderline, #NO = no global 
developmental delay/intellectual disability (mental retardation), only defect in the motor or speech development, NR = not relevant, * = < 0.05 
 
Table 3. Evaluation methods used in patients with neurodevelopmental disabilities 
 
 Distribution of evaluation methods in patients with different degrees of global developmental delay/intellectual disability (mental retardation)+ 
SP+ MO+ MI+ BL+ NO# Total 
B-L B W I B-L B W I B-L B W I B-L B W I B-L B W I B-L B W I 
No of 
patients 
5 7 0 87 4 6 3 23 12 9 8 22 2 6 5 16 0 5 2 19 23 33 18 167 
No = number of patients, +Degree of global developmental delay/intellectual disability (mental retardation): SP = severe to profound, MO = moderate,  
MI = mild, BL = borderline, #NO = no global developmental delay/intellectual disability (mental retardation), only defect in the motor or 
speech development, B-L = Brunet-Lézine test, B = Budapest Binet, W = Wechsler Intelligence Scale for Children – Fourth Edition, I = personal or  
telephone interview 
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Table 4. Classification of 241 patients with neurodevelopmental disability 
 
Subgroups             No (%) 
 
Neurodevelopmental disabilities without known prenatal, perinatal, and/or neonatal adverse events      
 Global developmental delay/intellectual disability (mental retardation)  
  Genetic syndromes with recognized aetiology      29 (12.0) 
  Children with dysmorphic features not recognized as specific syndromes   23 (9.5) 
  Children without recognized aetiology and dysmorphic features    45 (18.7) 
  Brain malformations          35 (14.5) 
  Inborn errors of metabolism            6 (2.5) 
  Leukoencephalopathies            4 (1.7) 
  Epileptic syndromes             4 (1.7) 
 Developmental (specific) language impairment        9 (3.7) 
 Neuromuscular disorders          12 (5.0) 
Neurodevelopmental disabilities subsequent known prenatal, perinatal, and/or neonatal adverse events  
 Cerebral palsy after preterm delivery        36 (14.9) 
 Cerebral palsy after delivery at term         20 (8.3) 
 Neurodevelopmental disabilities without cerebral palsy      18 (7.5) 
 
Total                           241 (100.0)   
 18 
 
    Subgroups without known prenatal, perinatal, and/or neonatal adverse events 
Genetic syndromes with recognized aetiology (Table 5) comprised 29 
patients, 15 boys and 14 girls (male/female ratio: 1.07) with mean age of 7.3 ± 4.7 years 
(age range: 1-18 years) at the last follow up. Syndromes with numerical/structural 
chromosomal abnormalities and single gene defects were included in this group. 
Trisomy 21 was found in 5 patients (Patients 1-5) and numerical anomalies of the sex 
chromosomes in 2 casas (Patients 16 and 17). Chromosomal structural anomalies were 
found in 4 boys and 6 girls (male/female ratio: 0.67, Patients 6-15) either by banding 
technique or FISH. FISH studies identified Prader-Willi (Patients 6-8), Williams 
(Patient 10) and DiGeorge (Patient 11) syndromes. Angelman syndrome occurred due 
to a rare de novo balanced translocation involving chromosome 15 (Patient 9). 
Molecular study with polymorphic short tandem repeat markers of the fibrillin-1 gene 
located in the region of 15q21.1 revealed that both chromosomes 15 were inherited 
from the father, therefore paternal uniparental disomy was proven as responsible for the 
Angelman syndrome. Patient 15 had a seemingly balanced translocation by G-band 
technique. Molecular testing was not available for cases with tuberous sclerosis 
(Patients 21, 22), neurofibromatosis 1 (Patient 23), VACTERL association (Patient 27) 
and one of the patients with Rett syndrome (Patient 19); however the diagnosis was 
evident on clinical grounds. Molecular genetic testing failed to reveal the aetiology of 
Cornelia de Lange (Patient 26) and blepharophimosis-mental retardation syndromes 
(Patients 28 and 29) until the time of writing. Visual impairment in 2 cases (Patients 12 
and 13) and hearing loss in 2 children (Patients 13 and 24) were part of the syndromes, 
and epilepsy occurred in 6 patients (Table 5). Moderate intellectual disability was the 
most frequent (34.5%) among these patient, followed by mild (27.6%) borderline 
(20.7%) and severe/profound (17.2%) disability (Tables 5, 17).  
Global developmental delay/intellectual disability (mental retardation) were 
associated with dysmorphic features without being recognized as specific 
syndromes (Table 6) in 23 children, 13 boys and 10 girls (male/female ratio: 1.30), and 
their mean age was 7.4 ± 4.0 years (age range: 2-16 years) at the last follow up.  The 
phenotypic anomalies observed on these patients are listed in Table 6. The parents of 3 
siblings (Patients 6, 7 and 8) and another child (Patient 9) were consanguineous (first 
cousins).  
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Table 5. Genetic syndromes with recognized aetiology 
 
Patient 
No 
Age* 
(years) 
Sex Diagnosis Intellectual 
disability+ 
Comments 
1 1 M M. Down MO Trisomy 21 
2 5 M M. Down MO Trisomy 21 
3 5 M M. Down MO Trisomy 21 
4 3 M M. Down MI Trisomy 21 
5 1 F M. Down BL Trisomy 21 
6 1 F Prader-Willi syndrome  MI 15q11-13 deletion (FISH) 
7 13 F Prader-Willi syndrome  MI 15q11-13 deletion (FISH) 
8 16 M Prader-Willi syndrome  MO 15q11-13 deletion (FISH) 
9 5 M Angelman syndrome  MI Epilepsy 
45,XY,der(15;15)(q10;q10) 
(Balanced 15q;15q translocation) 
10 8 M Williams syndrome BL 7q11.23 deletion (FISH) 
11 7 F DiGeorge syndrome  MI 22q11.2 deletion (FISH) 
12 5 F WAGR syndrome SP Visual impairment 
11p13 deletion 
13 6 F HDR (hypoparathyroidism, 
sensorineural deafness and renal 
dysplasia) syndrome 
SP Visual impairment  
Hearing impairment 
46,XX, del 10p(12.1):10qterm+ 
14 18 M Ring chromosome 22  SP Epilepsy 
Cerebellar vermis hypoplasia 
46,XY,r(22) 
15 8 F Chromosomal abnormality SP Atypical autism 
Blepharophimosis 
Cerebellar vermis hypoplasia 
46,XX,t(3q;16q)(2.6;2.4) 
16 6 M XXXXY syndrome BL  
17 13 F Triple X   BL 47, XXX, trisomy X 
18 3 M Fragile X syndrome MI FMR1gene: CGG repeat expansion 
(288-293 repeats) 
19 15 F Rett syndrome MO Epilepsy 
20 6 F Rett syndrome MO Epilepsy 
MECP2 gene: 
heterozygous deletion in exon 4 (44 
nucleotides)  
21 9 F Tuberous sclerosis MO Epilepsy 
22 14 M Tuberous sclerosis MI Epilepsy 
23 6 M Neurofibromatosis 1 MO  
24 13 M Waardenburg syndrome (WS1) BL Hearing impairment 
PAX3 gene: heterozygous deletion 
(c.751-757delTTCAGCT 
p.Phe129Glyfs*21) in exon 3  
25 6 M Myotonic dystrophy SP DMPK gene:  CTG repeat expansion 
26 3 M Cornelia de Lange syndrome MI No mutations in NIPBL and SMC1A 
genes 
27 5 F VACTERL association MO  
28 6 F Blepharophimosis-mental retardation 
syndrome 
BL Patients 28 and 29 are sisters 
Cerebellar vermis hypoplasia 
29 4 F Blepharophimosis-mental retardation 
syndrome 
MO Patients 28 and 29 are sisters 
aCGH negative 
No mutation in FOXL2 gene 
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, BL = borderline, aCGH = array comparative 
genome hybridization  
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Table 6. Global developmental delay/intellectual disability (mental retardation) 
   with dysmorphic features not recognized as specific syndromes 
 
Patient 
No 
Age* 
(years) 
Sex Phenotypic anomalies Intellectual 
disability+ 
Comments 
1 3 F Microcephaly, deeply-set eyes, large, long nose, short 
philtrum, everted lower lip, congenital heart disease: 
pulmonary stenosis, atrial septal defect,   
SP aCGH normal 
2 3 F Strabismus, broad nose, macrostomia, full upper lip SP Intrauterine growth retardation 
3 4 F Short stature, hypertelorism, epicanthi, small nose, 
anteversion of nares, long philtrum, high palate, low-set, 
abnormally modelled ears, muscle hypotonia and weakness    
SP Hearing impairment 
aCGH normal 
 
4 4 M Microcephaly, arched eyebrows, epicanthi, flat and wide 
nasal bridge, long philtrum, low-set, dysplastic ears  
SP  
5 5 F Hypertelorism, cleft palate, low-set, abnormally modelled 
ears, talipes equinovarus 
SP  
6 7 M Deeply-set eyes, abnormally modelled ears, macrostomia, 
thick upper lip 
SP Consanguineous parents (first 
cousins) 
Patients 6, 7 and 8 are brothers 
Patients 6 and 7 are twins 
Subtelomeric FISH: normal 
aCGH normal 
7 7 M Microcephaly, deeply-set eyes, dysplastic ears, 
macrostomia, thick upper lip  
SP Consanguineous parents (first 
cousins) 
Patients 7, 6 and 8 are brothers 
Patients 7 and 6 are twins 
8 16 M Deeply-set eyes, prominent, dysplastic ears, macrostomia,  
prominent lower jaw, truncal obesity  
SP Consanguineous parents (first 
cousins) 
Patients 8, 6 and 7 are brothers 
9 7 F Microcephaly, wide nasal bridge, epicanthi, clinodactyly, 
syndactyly of the toes II-III and III-IV 
SP Parental consanguinity 
 
10 8 F Prominent forehead, macrostomia, low-set, abnormally 
modelled ears, overriding toes 
SP  
11 8 M Microcephaly, strabismus, muscle hypotonia, pectus 
excavatum  
SP Epilepsy  
Visual impairment 
No mutations in ARX, MECP2, 
FOXG1 and CDKL5 genes 
12 10 F Microcephaly, ptosis, choanal stenosis, large nose, long 
fingers, partial syndactyly of toes II-III 
SP  
13 11 M Prominent forehead, flat, wide nasal bridge, epicanthi, thick 
upper lip, drooping lower lip, low-set ears, clinodactyly, 
hypermobility of small and large joints  
SP Intrauterine growth retardation 
14 12 M Deeply-set eyes, flat nasal bridge, short philtrum, 
macrostomia, low-set, prominent ears, short dig V, 
clinodactyly, hypotonia    
SP  
15 16 M Macrocephaly, narrow, elongated face, wide nasal bridge, 
hypertelorism, high palate 
SP Epilepsy 
16 4 M Microcephaly, frontal bossing, epicanthi, strabismus, 
narrow, elongated face, long philtrum, thick upper lip, 
abnormally shaped teeth, high palate, large, abnormally 
modelled ears 
MO MRI: occipital hypomyelination  
17 6 M Macrocephaly, micrognathia, anteversion of nares, pectus 
excavatum, hypotonia  
MO No mutation in NSD1 gene 
18 11 M Prominent forehead, wide, flat nasal bridge, epicanthi, thick 
upper lip, drooping lower lip, low-set ears, clinodactyly, 
wide-spaced nipples, joint hypermobility  
MO  
19 2 F Microcephaly, epicanthi, short philtrum, low-set, 
abnormally modelled ears 
MI  
Epilepsy 
20 2 M Macrocephaly, large, abnormally modelled ears, decreased 
flexion palmar creases   
MI  
21 6 M Short palpebral fissures, dental crowding, malocclusion, 
polydactyly (post-axial) on the left hand, short fingers, 
polydactyly and syndactyly on both feet, small penis and 
testes 
MI  
22 7 F Microcephaly, alopecia totalis, microstomia, short philtrum, 
pinched nose, arachnodactyly, skeletal muscle hypoplasia 
MI  
23 11 F Short stature, hypotelorism, kyphoscoliosis, increased 
lumbar lordosis, bowed femur and tibia, multiple naevi, 
hirsutism 
MI  
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, aCGH = array comparative genome  
hybridization  
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Intrauterine growth retardation occurred in two patients (Patients 2 and 13). 
Routine chromosomal studies, FMR1 gene testing and metabolic screening were normal 
for all cases and cranial MRI did not reveal any abnormalities except Patient 16, who 
had delayed occipital myelination. Subtelomeric FISH in one case (Patient 6) and array 
comparative genome hybridization in 3 children (Patients 1, 3 and 6) did not detect any 
abnormalities. Search for the aetiology by mutation analysis was not successful in 
finding any mutations in 2 cases (Patients 11 and 17). Visual loss was found in one 
patient (Patient 11) and hearing impairment occurred in another child (Patient 3) and 3 
patients (Patients 11, 15 and 19) were epileptic. The majority of patients (65.2%, 
p<0.05) suffered from severe/profound developmental delay/intellectual disability 
(mental retardation) in this group (Tables 6, 17). 
Global developmental delay/intellectual disability (mental retardation) 
occurred without any recognized aetiology and dysmorphic features (Table 7)  in 45 
patients, 23 boys and 22 girls (male/female ratio: 1.05) with a mean age of 7.7 ± 4.2 
years (age range: 2-18 years) at the last follow up. Two patients were siblings (Patients 
16 and 17). Routine chromosomal studies, FMR1 gene testing and metabolic screening 
were normal for all cases and cranial MRI did not reveal any abnormalities. Array 
comparative genome hybridization was available only for a single child (Patient 16) and 
it was normal. Mutation analysis for 3 patients (Patients 27, 29 and 40) did not identify 
any abnormalities in the genes tested. Epilepsy was diagnosed in 13 out of these 45 
children (28.9%). Almost half of these patients (46.7%, p<0.05) showed 
severe/profound defects in their cognitive functions, the cognitive impairment was mild 
in 28.9%, moderate in 15.5% and borderline in 8.9% (Tables 7, 17).  
Brain malformations (Table 8) were revealed by MRI in 35 children, 18 boys 
and 17 girls (male/female ratio: 1.06). Their mean age was 7.2 ± 3.5 years (age range: 
0.54-18 years) at the last follow up. Two patients (Patients 31 and 32) who were born 
from consanguineous parents and had pontocerebellar hypoplasia type 1 died in infancy, 
and another patient (Patient 27) with bilateral schizencephaly died at the age of 6 years.   
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Table 7. Global developmental delay/intellectual disability  
   (mental retardation) without recognized aetiology  
   and dysmorphic features 
   
Patient 
No 
Age* 
(years) 
Sex Intellectual 
disability+ 
Comments 
1 3 F SP  
2 3 F SP  
3 3 M SP  
4 4 F SP  
5 4 F SP Epilepsy 
6 4 F SP  
7 5 M SP  
8 5 F SP  
9 5 F SP Epilepsy 
10 5 F SP  
11 6 M SP  
12 8 M SP  
13 8 M SP Epilepsy 
14 8 F SP  
15 8 M SP  
16 8 M SP Patients 16 and 17 are siblings 
aCGH normal 
17 18 F SP Patients 17 and 16 are siblings 
18 9 F SP  
19 10 F SP  
20 17 F SP  
21 18 M SP Epilepsy 
22 4 M MO  
23 7 M MO  
24 8 M MO  
25 9 M MO  
26 9 F MO Epilepsy 
27 9 M MO Epilepsy 
No mutation in SCN1A gene 
28 10 M MO  
29 2 M MI Epilepsy 
No mutation in SLC2A1 gene 
30 3 M MI  
31 5 M MI  
32 5 F MI  
33 5 M MI  
34 6 M MI  
35 7 M MI  
36 8 M MI  
37 11 M MI Epilepsy 
38 11 F MI  
39 13 F MI Epilepsy 
40 13 F MI Epilepsy 
No mutation in PCDH19 gene 
41 14 F MI Epilepsy 
42 2 F BL  
43 5 F BL Epilepsy 
44 7 M BL  
45 16 F BL Epilepsy 
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of  
global developmental delay/intellectual disability (mental retardation): SP = severe 
to profound, MO = moderate, MI = mild, BL = borderline, aCGH =  
array comparative genome hybridization  
 
 23 
 
 
Table 8. Brain malformations 
 
Patient 
No 
Age* 
(years) 
Sex Malformation Intellectual 
disability+ 
Comments 
1 14 F Holoprosencephaly SP Visual impairment 
2 13 M Agenesis of the corpus callosum SP Epilepsy 
3 2 M Corpus callosum and vermis 
hypoplasia 
MI  
4 11 M Corpus callosum and vermis 
hypoplasia 
SP  
5 3 F Corpus callosum, vermis and optic 
nerve hypoplasia 
BL Visual impairment 
6 9 F Corpus callosum, vermis and optic 
nerve hypoplasia 
MI Epilepsy  
Visual impairment 
7 4 F Corpus callosum, vermis and white 
matter hypoplasia  
SP Epilepsy 
8 1 M Agenesis of the corpus callosum 
Greig cephalosyndactily syndrome 
BL GLI3 gene: heterozygous deletion of exon 2 
9 4 F Acrocallosal syndrome MO Visual impairment  
Hearing impairment 
aCGH normal 
No mutation in KIF7 and GLI3 genes 
10 7 F Wide cavum septi pellucidi MO  
11 13 F Wide cavum septi pellucidi SP  
12 7 F Microcephaly SP  
13 7 F Microcephaly SP  
14 1 M Micrencephaly with simplified 
gyral pattern, hypoplasia of the 
corpus callosum and cerebellum  
SP Epilepsy  
Visual impairment 
Hearing impairment 
15 2 M Megalencephaly SP  
16 5 M Megalencephaly BL  
17 13 F Bilateral pachygyria SP  
18 11 M Lissencephaly (agyria-pachygyria) SP Cerebral palsy: spastic quadriplegia  
Epilepsy 
Visual impairment 
Hearing impairment 
LIS1gene : heterozygous deletion (c.83-
84delAT, p.Tyr28Phefs*31) 
19 12 F Subcortical band heterotopia MI Epilepsy 
DCX gene: heterozygous deletion (c.200delG, 
p.Ile68Leufs*87) 
20 11 M Bilateral polymicrogyria SP Cerebral palsy: spastic quadriplegia 
21 12 M Bilateral polymicrogyria and mega 
corpus callosum 
MO Cerebral palsy: spastic hemiplegia on the left 
side  
Epilepsy 
aCGH normal 
No mutation in VPS13B gene 
22 14 M Schizencephaly on the left side and 
polymicrogyria on the right side  
MI Cerebral palsy: spastic hemiplegia on the right 
side  
Epilepsy 
23 8 F Schizencephaly on the left side NO Cerebral palsy: spastic hemiplegia on the right 
side 
24 1 M Bilateral schizencephaly SP Cerebral palsy: spastic quadriplegia  
Epilepsy 
25 2 F Bilateral schizencephaly SP Hypotonic cerebral palsy 
26 5 M Bilateral schizencephaly SP Cerebral palsy: spastic quadriplegia  
Epilepsy 
Visual impairment 
27 6 M Bilateral schizencephaly SP Cerebral palsy: spastic quadriplegia  
Epilepsy 
Visual impairment 
Died at the age of 6 years 
28 11 F Bilateral opercular hypoplasia MI Pseudobulbar paresis 
29 18 M Vermis and optic nerve hypoplasia MO  
30 5 M Molar tooth malformation (Joubert 
syndrome) 
SP Visual impairment 
CEP290 gene: 
Allele 1: mutation in exon 38 (c.5182G>T, 
p.Glu1728Stop) from the father 
Allele 2: mutation in exon 46 (c.6277delG, 
p.Val2093SerfsStop4) from the mother 
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Table 8. Brain malformations (continued) 
31 0,4 
(4,5m) 
M Pontocerebellar hypoplasia type 1 SP Consanguineous parents 
Visual impairment 
Hearing impairment 
Generalized hypotonia 
No development 
EXOSC3 gene: homozygous mutation 
(c.92G>C p.Gly31Ala) in exon 1 
Died at the age of 4,5 months 
32 0,6 
(7m) 
F Pontocerebellar hypoplasia type 1 SP Consanguineous parents 
Visual impairment  
Hearing impairment 
Generalized hypotonia 
No development 
EXOSC3 gene: homozygous mutation 
(c.92G>C p.Gly31Ala) in exon 1 
Died at the age of 7  months 
33 3 F Pontocerebellar hypoplasia SP Generalized hypotonia 
CASK gene: heterozygous mutation 
(c.1034delG p.Arg345Lysfs*24) in exon 12  
34 7 F Pontocerebellar hypoplasia SP Cerebral palsy: spastic quadriplegia 
Epilepsy  
Visual impairment 
Hearing impairment 
No mutation in CASK and TSEN54 genes 
35 10 M Vena Galeni aneurysm BL  
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, BL = borderline, NO = no global 
developmental delay/intellectual disability (mental retardation), only defect in the motor development, aCGH = array comparative 
genome hybridization  
 
The various types of malformations are listed in Table 8. Anomalies of the 
corpus callosum (Patients 2-9) and schizencephaly (Patients 22-27) were the most 
frequent malformations in this series of patients. Chromosomal abnormalities or inborn 
errors of metabolism were not found by routine testing. Array comparative genome 
hybridization failed to reveal any abnormalities in 2 cases (Patients 9 and 21). 
Molecular genetic studies identified mutations in Patients 8, 18, 19, 30, 31/32, and 33 in 
the GLI3, LIS1, DCX, CEP290, EXOSC3 and CASK genes, respectively, which means 
that in 20% of brain malformations the molecular background was detected (Table 8). 
Mutation analysis in another 3 patients (Patients 9, 21 and 34) did not identify any 
mutations in the genes tested (Table 8). Cerebral palsy occurred in 10 cases (28.6%) 
visual impairment in 12 (34.3%), and hearing loss in 6 patients (17.1%). Epileptic 
seizures appeared in 12 children (34.3%). As shown in Tables 8 and 17, the vast 
majority (60.0%, p<0.05) of patients with brain malformations had severe/profound 
global developmental delay/intellectual disability (mental retardation).  
Inborn errors of metabolism (Table 9) were diagnosed in 6 cases, 5 boys and 
one girl (male/female ratio: 5:1), their mean age was 8.5 ± 7.8 years (age range: 2-22 
years) at the last follow up. Mutations in the HPRT gene were identified in three 
patients (Patients 1-3) with the X-linked Lesch-Nyhan syndrome, two of them were 
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relatives. Mutations in the mitochondrial DNA occurred in another three patients, one 
with Leigh syndrome (Patient 4) and 2 with Kearns-Sayre syndrome (Patients 5 and 6). 
Visual impairment was observed in all 3 children with mitochondrial disease and 
hearing impairment appeared in 2 patients (Patients 5 and 6) with Kearns-Sayre 
syndrome. The child with Leigh syndrome (Patient 4) died at the age of 4 years and one 
of the Kearns-Sayre cases (Patient 6) at the age of 22 years. Two patients in this group 
(Patients 3 and 5) had severe/profound intellectual disability; the cognitive defect was 
moderate in 3 children (Patients 1, 2 and 4) and mild in one (Patient 6) child (Tables 9, 
17). 
Table 9. Inborn errors of metabolism 
 
Patient 
No 
Age* 
(years) 
Sex Diagnosis Intellectual 
disability+ 
Comments 
1 2 M Lesch-Nyhan syndrome MO HPRT gene: hemizygous mutation (c.609+1G>A) with 
change in the first base after exon 8, probably leading to 
defective splicing 
2 4 M Lesch-Nyhan syndrome MO HPRT gene: hemizygous mutation (c.151C>T p.Arg51*) 
in exon 3 
The mothers of  Patients 2 and 3 are sisters 
3 5 M Lesch-Nyhan syndrome SP HPRT gene: hemizygous mutation (c.151C>T p.Arg51*) 
in exon 3 
The mothers of  Patients 3 and 2 are sisters  
4 4 F Leigh syndrome MO Visual impairment 
Mitochondrial ND5 gene mutation (m.13513G>A), 60-
70% heteroplasmy rate  
Died at the age of 4 years 
5 14 M Kearns-Sayre syndrome SP Epilepsy  
Visual impairment  
Hearing impairment  
Mitochondrial DNA (m.8646_15647del) deletion 
Died at the age of 14 years 
6 22 M Kearns-Sayre syndrome MI Visual impairment (pigmentary degeneration of the 
retina) 
Hearing impairment  
Mitochondrial DNA deletion 
Died at the age of 22 years 
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild 
  
Leukoencephalopathies (Table 10) were diagnosed in 4 cases, 2 boys and 2 
girls (male/female ratio: 1.00). Their mean age was 4.4 ± 4.0 years (age range: 0.5-8 
years) at the last follow up. Clinical features and abnormal brain MRI were the clues to 
the diagnosis in Alexander disease (Patient 1), X-linked adrenoleukodystrophy (Patient 
2) and Krabbe disease (Patient 3). Metabolic tests (Patients 2 and 3) and mutation 
analysis of the GFAP, ABCD1 and GALC genes (Patients 1, 2 and 3, respectively) 
confirmed the diagnosis in 3 cases. In spite of an extended molecular genetic search 
(mutation testing of the PLP1, GJA12/GJC, FAM126A2 and POLR3A/POLR3B genes) 
the aetiology remained unknown in Patient 4. Visual impairment was obvious in Patient 
2 with X-linked adrenoleukodystrophy at the last follow up and epilepsy occurred in 
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Patients 2 and 3. Patient 1 with infantile form of Alexander disease died at the age of 
one year. The global developmental delay/intellectual disability was severe/profound in 
patients with Alexander disease and X-linked adrenoleukodystrophy, moderate in the 
infant with Krabbe disease at 6 months of age and mild in Patient 4, who suffered from 
leukoencephalopathy of unknown aetiology (Tables 10, 17). 
Table 10. Leukoencephalopathies 
 
Patient 
No 
Age* 
(years) 
Sex Diagnosis Intellectual 
disability+ 
Comments 
1 1 F Alexander disease SP GFAP gene: heterozygous mutation (c.1175C>T 
p.Thr392Ile) in exon 8 
Died at the age of 1 year 
2 8 M X-linked 
adrenoleukodystrophy 
SP Epilepsy 
Visual impairment 
Accumulation of very long chain fatty acids 
ABCD1 gene: mutation (c.631C>T p.Leu211Phe) in exon 
1 
3 0.5 
(6m) 
F Krabbe disease MO Epilepsy 
Low activity of galactocerebroside-beta galactosidase 
GALC gene:  
Allele 1: heterozygous mutation (c.1586C>T 
p.Thr529Met) in exon 14 
Allele 2: heterozygous deletion of exons 11-17 
4 8 M Leukoencephalopathy 
with unknown aetiology 
MI No mutation in PLP1, GJA12/GJC, FAM126A2, POLR3A 
and POLR3B genes 
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild 
 
Epileptic syndromes (Table 11) were responsible for the neurodevelopmental 
disability in 4 patients, 2 girls and 2 boys (male/female ratio: 1.00) with mean age of 4.8 
± 4.5 years (age range 1-11 years). Devastating infantile migrating partial seizures in 
association with visual, hearing impairment and severe/profound disability occurred in 2 
girls (Patients 1 and 2) and West syndrome started in infancy in 2 boys (Patients 3 and 
4) who were left with mild cognitive disability later (Tables 11, 17). The aetiology of 
the epileptic syndromes was not identified.  
Table 11. Epileptic syndromes 
 
Patient 
No 
Age* 
(years) 
Sex Diagnosis Intellectual 
disability+ 
Comments 
1 1 F Malignant migrating partial seizures 
in infancy (unknown aetiology) 
SP Visual impairment  
Hearing impairment 
2 11 F Malignant migrating partial seizures 
in infancy (unknown aetiology)  
SP Visual impairment  
Hearing impairment 
3 2 M West syndrome (unknown aetiology) MI  
4 5 M West syndrome (unknown aetiology) MI  
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MI = mild 
 
Developmental (specific) language impairment (Table 12) was found in 9 
boys. Their mean age was 7.7 ± 2.8 years (age range: 4-12 years) at the last follow up. 
Four boys (Patients 1-4) had borderline cognitive impairment, while intellectual 
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disability was not revealed by neuropsychological testing in 5 boys (Patients 5-9, Tables 
12, 17). No aetiology was found in any of these patients (Table 12).  
 
Table 12. Developmental (specific)  
     language impairment 
 
Patient 
No 
Age* 
(years) 
Sex Intellectual 
disability+ 
1 5 M BL 
2 8 M BL 
3 10 M BL 
4 12 M BL 
5 4 M NO 
6 5 M NO 
7 6 M NO 
8 9 M NO 
9 10 M NO 
No = number of patients, *Age at last follow  
up, M = male +Degree of global developmental  
delay/intellectual disability (mental retardation):  
BL = borderline, NO = no global  
developmental delay/intellectual disability  
(mental retardation), only delay in the speech  
development  
 
Neuromuscular disorders (Table 13) comprised a group of 12 children, 7 boys 
and 5 girls (male/female ratio: 1.40). The mean age was 9.8 ± 5.8 years (age range 4-21 
years) at the last follow up. Patient 1 with spinal muscular atrophy type 1 was supported 
by mechanical ventilation and died at the age of 4 years. Patients 2-4 suffered from 
spinal muscular atrophy type 2 and had serious defect in their motor development. 
Delay in the motor development was also observed in patients with congenital 
myasthenia (Patient 5), nemaline (Patients 6 and 7), myotubular (Patient 8) and 
centronuclear (Patient 9) myopathies. Two boys (Patients 10 and 11) had Duchenne 
muscular dystrophy and a young man (Patient 12) was diagnosed with 
facioscapulohumeral dystrophy. Molecular genetic studies of the SMN1, CHRNE, NEB, 
MTM1 and DMD genes confirmed the diagnoses as shown in Table 13. Contraction of 
the D4Z4 repeat on chromosome 4q35 was identified in the patient with 
facioscapulohumeral dystrophy. Molecular testing was not successful so far only for 2 
children (Patients 7 and 9). There was no intellectual disability in 58.4%  (p<0.05) of 
the patients; it was mild in 25.0%, moderate in 8.3% and severe/profound also in 8.3% 
(Tables 13, 17).   
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Table 13. Neuromuscular disorders 
 
Patient 
No 
Age* 
(years) 
Sex Diagnosis Intellectual 
disability+ 
Comments 
1 4 F Spinal muscular atrophy 
type 1 
NO SMN1 gene: homozygous deletion exons 7 and 8  
Died at the age of 4 years 
2 6 F Spinal muscular atrophy 
type 2 
NO SMN1 gene: homozygous deletion exons 7 and 8 
3 7 F Spinal muscular atrophy 
type 2 
NO SMN1 gene: homozygous deletion exons 7 and 8 
4 12 F Spinal muscular atrophy 
type 2 
NO SMN1 gene: homozygous deletion exons 7 and 8 
5 8 F Congenital myasthenia NO CHRNE gene: homozygous mutation (c.1267delG 
p.422fs*) in exon 12 
6 6 M Nemaline myopathy MI NEB gene: 
Allele 1: mutation  in exon 174  
(c.24527_24528delCT p.P8176fs) from the father  
Allele 2: mutation in exon 171 
(c.24250_24253dupGTCA p.T8085fs) from the mother 
7 6 M Nemaline myopathy NO No mutation in ACTA1, TPM2, TPM3 and NEB genes 
8 7 M Myotubular myopathy (X-
linked) 
SP MTM1 gene: heterozygous mutation (c.1315_1316insT 
p.439fs*) in exon 12  
9 5 M Centronuclear myopathy NO No mutation in BIN1 gene  
10 19 M Duchenne muscular 
dystrophy 
MI DMD gene: deletion exons 45 to 52 
Patients 10 and 11 are brothers 
11 21 M Duchenne muscular 
dystrophy 
MO DMD gene: deletion exons 45 to 52 
Patients 11 and 10 are brothers 
12 16 M Facioscapulohumeral 
dystrophy 
MI Contraction of the D4Z4 repeat on chromosome 4q35 
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, NO = no global developmental 
delay/intellectual disability (mental retardation), only defect in the motor development 
 
Subgroups with known prenatal, perinatal, and/or neonatal adverse events 
Cerebral palsy after preterm delivery (Table 14) was diagnosed in 36 
children, 20 boys and 16 girls (male/female ratio: 1.25). Their mean age was 5.8 ± 3.7 
years (age range 1-20 years) at the time of the last follow up. Eleven patients (30.6%, 6 
boys and 5 girls) were born from twin pregnancy, one of them (Patient 4) after in vitro 
fertilization. Intrauterine growth retardation occurred in 2 cases (Patients 5 and 6). 
Spastic quadriplegia was observed in 19 patients (52.8%), spastic diplegia in 9 (25%) 
and spastic hemiplegia in 7 children (19.4%). Mixed form of cerebral palsy was found 
in one patient. Some details of perinatal data, adverse events and findings by 
neuroimaging can be found in Table 14. Visual loss occurred in 7 patients (19.4%), 
hearing impairment in 4 (11.1%) and epilepsy in 10 (27.8%) children (Table 14). The 
global developmental delay/intellectual disability (mental retardation) was 
severe/profound in 41.7% (p<0.05), moderate, mild and borderline in 5.6%, 11.1% and 
22.2%, respectively, while 19.4% of the patients showed normal intellectual abilities 
(Tables 14, 17). 
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Table 14. Cerebral palsy after preterm delivery 
 
Patient 
No 
Age* 
(years) 
Sex Gestational 
age (weeks) 
Birth 
weight 
(g) 
Adverse events 
Abnormalities found 
by brain imaging   
Type of cerebral 
palsy 
Intellectual 
disability+ 
Comments 
1 1 M 34 2420 Twin pregnancy, twin-
twin transfusion 
syndrome 
Hydranencephaly 
Spastic 
quadriplegia 
SP Epilepsy  
Visual impairment 
Hearing 
impairment 
2 2 F 37 2250 Twin pregnancy 
Intrapartum asphyxia 
Spastic 
quadriplegia 
SP Visual impairment 
Hearing 
impairment 
Died at the age of 
2 years 
3 2 M 33 1490 Intrauterine CMV 
infection 
Spastic 
quadriplegia 
SP Epilepsy  
Visual impairment 
Hearing 
impairment 
4 2 M 31 1700 IVF, twin pregnancy 
PWMI 
Spastic 
quadriplegia 
SP Epilepsy 
West syndrome 
5 3 M 31 990 Intrauterine growth 
retardation 
GMH-IVH, PWMI 
Spastic 
quadriplegia 
SP Epilepsy 
6 4 F 31 860 Intrauterine growth 
retardation  
PWMI 
Spastic 
quadriplegia 
SP  
7 4 F 30 1340 GMH-IVH, PWMI 
Ventriculitis  
 
Spastic 
quadriplegia 
SP Epilepsy 
Visual impairment 
Hearing 
impairment 
8 6 M 30 1510 Twin pregnancy 
PWMI  
Spastic 
quadriplegia 
SP  
9 7 M 35 2180 GMH-IVH, PWMI 
Hydrocephalus 
Spastic 
quadriplegia 
SP Epilepsy 
10 8 F 28 1190 GMH-IVH, PWMI Spastic 
quadriplegia 
SP  
11 8 M 30 1690 PWMI Spastic 
quadriplegia 
SP  
12 9 M 33 1320 PWMI Spastic 
quadriplegia 
SP  
13 10 F 27 1380 PWMI Spastic 
quadriplegia 
SP Epilepsy 
14 11 F 33 1290 PWMI Spastic 
quadriplegia 
SP Visual impairment 
15 2 F 30 1490 PWMI Spastic 
quadriplegia 
MO  
16 2 M 31 1900 PWMI Spastic 
quadriplegia 
MI  
17 3 M 32 1650 PWMI Spastic 
quadriplegia 
MI  
18 6 M 32 1910 Twin pregnancy 
PWMI 
Spastic 
quadriplegia 
MI Epilepsy 
19 6 M 35 2460 PWMI Spastic 
quadriplegia 
BL  
20 2 M 32 1800 PWMI Spastic diplegia BL  
21 4 M 31 1400 PWMI Spastic diplegia BL  
22 5 F 26 960 PWMI Spastic diplegia BL  
23 6 F 29 1460 Twin pregnancy 
PWMI 
Spastic diplegia BL  
24 8 M 28 990 PWMI Spastic diplegia BL Visual impairment 
25 10 M 30 1200 Twin pregnancy 
PWMI 
Spastic diplegia BL  
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Table 14. Cerebral palsy after preterm delivery (continuation) 
 
26 5 F 31 1900 PWMI Spastic diplegia NO  
27 7 F 30 1290 Twin pregnancy 
PWMI 
Spastic diplegia NO  
28 6 M 31 2380 Diabetic foetopathy 
PWMI 
Spastic diplegia NO  
29 3 M 29 1430 GMH-IVH 
Periventricular 
haemorrhagic 
infarction on the right 
side 
Hydrocephalus 
Spastic 
hemiplegia on the 
left side 
MO  
30 10 F 30 1300 Asymmetrical PWMI 
more severe on the 
right side 
Spastic 
hemiplegia on the 
left side 
MI  
31 8 M 27 990 Asymmetrical PWMI 
more severe on the left 
side 
Spastic 
hemiplegia on the 
right side 
BL Epilepsy 
32 4 F 30 1780 Twin pregnancy 
PWMI 
Spastic 
hemiplegia on the 
right side 
NO  
33 5 F 26 840 GMH-IVH  
Periventricular 
haemorrhagic 
infarction on the right 
side 
Spastic 
hemiplegia on the 
left side 
NO  
34 6 M 32 1770 Twin pregnancy 
Intrapartum asphyxia 
Asymmetrical PWMI 
more severe on the 
right side 
Spastic 
hemiplegia on the 
left side 
NO  
35 20 F 32 1720 Placental abruption 
Asymmetric PWMI 
more severe on the 
right side 
Spastic 
hemiplegia on the 
left side 
NO Epilepsy 
36 3 F 23 630 Twin pregnancy 
GMH-IVH 
Mixed form 
(spastic and 
extrapyramidal) of 
cerebral palsy 
SP Visual impairment 
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, BL = borderline, NO = no global 
developmental delay/intellectual disability (mental retardation), only defect in the motor development, CMV = cytomegalovirus, 
IVF = in vitro fertilisation, PWMI = periventricular white matter injury, GMH-IVH = germinal matrix-intraventricular haemorrhage  
 
Cerebral palsy after delivery at term (Table 15) developed in 20 children, 10 
boys and 10 girls (male/female ratio: 1.00), one girl (Patient 12) was born from twin 
pregnancy. The mean age was 6.4 ± 3.6 years (age range: 2-16 years) in this group at 
the last follow up. Intrauterine growth retardation occurred in 3 cases (15.0%, Patients 
11, 13 and 19). Spastic quadriplegia was diagnosed in 10 (50.0%), spastic hemiplegia in 
9 (45.0%) patients and extrapyramidal type of cerebral palsy was found in one case. The 
details of perinatal data, suspected aetiology and findings by neuroimaging can be found 
in Table 15. Visual loss occurred in 3 patients (15.0%) hearing impairment in 2 (10.0%) 
and epilepsy in 4 (20.0%) children (Table 15). The global developmental 
delay/intellectual disability (mental retardation) was severe/profound in 40.0%, 
moderate, mild and borderline in 15.0%, 5.0% and 10.0%, respectively, while 30.0% of 
the patients showed normal intellectual abilities (Tables 15, 17). 
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Table 15. Cerebral palsy after delivery at term 
 
Patient 
No 
Age* 
(years) 
Sex Gestational 
age (weeks) 
Birth 
weight 
(g) 
Adverse events 
Abnormalities found 
by brain imaging   
Type of cerebral 
palsy 
Intellectual 
disability+ 
Comments 
1 
 
16 M 39 2760 Intrapartum asphyxia Spastic 
quadriplegia 
SP Epilepsy 
2 
 
11 F 41 3700 Intrapartum asphyxia Spastic 
quadriplegia 
SP  
3 2 M 38 3000 Intrapartum asphyxia Spastic 
quadriplegia 
SP  
4 5 F 41 2600 Intrapartum asphyxia Spastic 
quadriplegia 
SP Epilepsy 
5 4 M 39 4000 Intrapartum asphyxia Spastic 
quadriplegia 
SP  
6 9 M 37 3200 Intrapartum asphyxia Spastic 
quadriplegia 
SP Epilepsy 
Visual impairment 
Hearing 
impairment 
7 2 F 40 3700 Intrapartum asphyxia Spastic 
quadriplegia 
SP Visual impairment 
Hearing 
impairment 
8 7 F 37 3040 Neonatal bacterial 
meningitis 
Spastic 
quadriplegia 
SP  
9 3 M 41 3970 Intrapartum asphyxia Spastic 
quadriplegia 
MO Visual impairment 
10 8 M 39 2870 Neonatal bacterial 
meningitis 
Spastic 
quadriplegia 
NO Epilepsy 
11 11 F 39 1930 Intrauterine growth 
retardation  
Spastic 
hemiplegia on the 
left side 
MO  
12 3 F 37 2750 Twin pregnancy 
Asymmetrical PWMI 
more severe on the 
right side 
Spastic 
hemiplegia on the 
left side  
MI  
13 9 F 40 2400 Intrauterine growth 
retardation 
Spastic 
hemiplegia on the 
right side 
BL  
14 3 M 40 3310 Intrapartum asphyxia Spastic 
hemiplegia on the 
right side 
BL  
15 7 F 39 3200 Neonatal stroke on the 
right side 
Spastic 
hemiplegia on the 
left side 
NO  
16 4 F 40 3350 Neonatal stroke on the 
right side 
Spastic 
hemiplegia on the 
left side 
NO  
17 8  M 40 3140 Neonatal infection Spastic 
hemiplegia on the 
left side 
NO  
18 6 M 38 3430 Intrapartum asphyxia 
Neonatal stroke on the 
left side 
Spastic 
hemiplegia on the 
right side 
NO  
19 3 F 38 2390 Intrauterine growth 
retardation 
Spastic 
hemiplegia on the 
right side 
NO  
20 7 M 38 3200 Intrapartum asphyxia Extrapyramidal 
cerebral palsy 
MO  
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, BL = borderline, NO = no global 
developmental delay/intellectual disability (mental retardation), only defect in the motor development, PWMI = periventricular 
white matter injury 
 
Neurodevelopmental disabilities subsequent known prenatal, perinatal, 
and/or neonatal adverse events but without cerebral palsy (Table 16) comprised 18 
patients, 7 boys and 11 girls (male/female ratio: 0.64) with a mean age of 8.2 ± 5.3 
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years (age range: 2-20 years). Intrauterine growth retardation occurred in 3 cases 
(16.67%, Patients 9, 14 and 15). The details of perinatal data, suspected aetiology and 
findings by neuroimaging can be found in Table 16. Visual impairment occurred in 3 
patients (16.7%) hearing loss in 2 (11.1%) and epilepsy in 2 (11.1%) children (Table 
16). The global developmental delay/intellectual disability (mental retardation) was 
severe/profound, or mild in 44.4% (p<0.05), while the classification criteria excluded 
patients with normal intellectual abilities from this subgroup (Tables 16, 17). 
Table 16. Neurodevelopmental disabilities subsequent known prenatal, perinatal, 
     and/or neonatal adverse events without cerebral palsy  
 
Patient 
No 
Age* 
(years) 
Sex Gestational 
age 
Birth 
weight 
(g) 
Adverse events 
Abnormalities found by brain imaging   
Intellectual 
disability+ 
Comments 
1 7 F 36 2300 Preeclampsia, placental insufficiency SP Epilepsy 
2 5 M 27 740 Prematurity 
GMH-IVH, PWMI 
SP Visual impairment 
3 9 F 30 1400 Prematurity 
PWMI 
SP Visual impairment 
4 9 F ? 2500 Foetal alcohol syndrome SP  
5 3 F 23 630 Prematurity 
GMH-IVH, PWMI 
SP Visual impairment 
6 18 M 36 2380 Prematurity SP  
7 20 F 41 3900 Neonatal bacterial meningitis SP  
8 3 F 40 3420 Intrauterine CMV infection SP Hearing 
impairment 
9 17 M 40 2520 Intrauterine growth retardation MO Epilepsy 
10 10 F 38 3440 Neonatal asphyxia MI  
11 6 F 39 4750 Intrapartum asphyxia MI  
12 5 F 37 2220 Twin-twin transfusion syndrome MI  
13 6 M 36 2280 Intrapartum asphyxia MI  
14 9 F 38 1980 Intrauterine growth retardation MI  
15 2 M 34 1800 Intrauterine growth retardation 
Prematurity 
Intrapartum asphyxia 
MI  
16 5 M 38 3370 Threatened miscarriage MI  
17 3 F 39 2800 Intrauterine CMV infection MI Hearing 
impairment 
18 10 M 35 2270 Placental abruption 
Prematurity 
Intrapartum asphyxia 
BL  
No = number of patients, *Age at last follow up, M = male, F = female, +Degree of global developmental delay/intellectual 
disability (mental retardation): SP = severe to profound, MO = moderate, MI = mild, BL = borderline, CMV = cytomegalovirus, 
GMH-IVH = germinal matrix-intraventricular haemorrhage, PWMI = periventricular white matter injury  
 
Distribution of different severity categories of global developmental 
delay/intellectual disability (mental retardation) in the various subgroups of 
neurodevelopmental disabilities in our series of patients is demonstrated on Table 17. 
The cognitive disability was severe/profound in 41.5% (p<0.05) of the total of 241 
patients; it was moderate, mild or borderline in 14.5%, 21.2% and 12.0%, respectively. 
Defect only in the motor or speech development without global developmental 
delay/intellectual disability (mental retardation) was found in 10.8% of patients, the 
majority of them occurred in the groups with developmental language impairment, 
neuromuscular disorders and cerebral palsy (Table 17). 
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The occurrence of cerebral palsy (27.4% of the total 241 patients), epilepsy 
(23.6%), visual (14.0%) and hearing (8.7%) impairment, the combination of these 
complications and their distribution in various categories of global developmental 
delay/intellectual disability (mental retardation) are demonstrated on Table 18. It can be 
seen that cerebral palsy, epilepsy, sensory losses and their combination were most 
common in patients with severe/profound cognitive defect (Table 18).  
Since the classification of patients into various subgroups rested mainly on 
aetiological bases, the aetiological yield was very high in certain subgroups (i.e. genetic 
syndromes with recognized aetiology, or neurodevelopmental disabilities subsequent 
known prenatal, perinatal, and/or neonatal adverse events, etc.), while the aetiology 
remained unknown in all patients in other subgroups (i.e. children with dysmorphic 
features not recognized as specific syndromes, or developmental language impairment, 
etc.). Overall the aetiology of neurodevelopmental disabilities was identified in 66.4% 
of the 241 children (Table 19). Well documented genetic diagnosis (chromosomal 
numerical/structural abnormalities, or single gene defects) was established in 19.5% of 
the entire study population. This figure grew up to 28.1% if the number of positive test 
results was related only to the first major group of patients without known prenatal, 
perinatal, and/or neonatal adverse events. 
  
Table 17. Distribution of severity of global developmental delay/intellectual disability (mental retardation) in  
     different subgroups of patients with neurodevelopmental disability  
      
 
 
 
Patient subgroups 
 
No. of patients in different categories of global developmental delay/intellectual disability (mental 
retardation)+ 
 
 SP+  MO+  MI+  BL+  NO# 
 
Total 
No (%)  No (%) No (%) No (%) No (%) No (%) 
No adverse events       
  Global developmental delay/intellectual disability       
        Genetic syndromes with recognized aetiology 5 (17.2)  10 (34.5)  8 (27.6)  6 (20.7)  0 29 (100) 
        Children with dysmorphic features not recognized as 
        specific syndromes* 
15 (65.2)a 3 (13.1) 5 (21.7) 0 0 23 (100) 
        Children without recognized aetiology or dysmorphic 
        features* 
21 (46.7)a 7 (15.5) 13 (28.9) 4 (8.9) 0 45 (100) 
        Brain malformations* 21 (60.0)a 4 (11.4) 5 (14.3) 4 (11.4) 1 (2.9) 35 (100) 
        Inborn errors of metabolism 2 3 1 0 0 6 
        Leukoencephalopathies 2 1 1 0 0 4 
        Epileptic syndromes 2 0 2 0 0 4 
   Developmental (specific)  language impairment 0 0 0 4 5 9 
   Neuromuscular disorders* 1 (8.3) 1 (8.3) 3 (25.0) 0 7 (58.4)a 12 (100) 
Adverse events (prenatal, perinatal, neonatal)       
   Cerebral palsy after preterm delivery* 15 (41.7)a 2 (5.6) 4 (11.1) 8 (22.2) 7 (19.4) 36 (100) 
   Cerebral palsy after delivery at term 8 (40.0) 3 (15.0) 1 (5.0) 2 (10.0) 6 (30.0) 20 (100) 
   Neurodevelopmental disabilities without cerebral palsy* 8 (44.4)a 1 (5.6) 8 (44.4) a 1 (5.6) 0 18 (100) 
Total* 100 (41.5)a 35 (14.5) 51 (21.2) 29 (12.0) 26 (10.8) 241 (100) 
No = number of patients, % = percentage of the total number of patients in each subgroup, +Degree of global developmental delay/intellectual disability: SP = severe  
to profound, MO = moderate, MI = mild, BL = borderline, #NO = no global developmental delay/intellectual disability, only defect in the motor or speech development, 
* = The distribution of the degrees of global developmental delay/intellectual disability significantly differs from uniform distribution (p<0.05),  
a = Largest deviation from the uniform distribution (maximal Pearson residual)  
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Table 18. Distribution of cerebral palsy, epilepsy, visual and hearing impairments in different categories of global  
     developmental delay/intellectual disability  
 
 
 
 
 
 
No. of patients with various impairments in different categories of global developmental delay/intellectual disability+ 
  
 SP+  MO+  MI+  BL+  NO# 
 
Total 
No (%)  No (%) No (%) No (%) No (%) No (%) 
Cerebral palsy 30 (12.4) 6 (2.5) 6 (2.5) 10 (4.2) 14 (5.8) 66 (27.4) 
Epilepsy 30 (12.4) 8 (3.3) 14 (5.8) 3 (1.2) 2 (0.8) 57 (23.6) 
Visual impairment 27 (11.2) 3 (1.2) 2 (0.8) 2 (0.8) 0 34 (14.0) 
Hearing impairment 17 (7.1) 1 (0.4) 2 (0.8) 1 (0.4) 0 21 (8.7) 
Two of these impairments 14 (5.8) 3 (1.2) 4 (1.6) 2 (0.8) 2 (0.8) 25 (10.2) 
Three of these impairments 8 (3.3) 0 0 0 0 8 (3.3) 
Four of these impairments 6 (2.5) 0 0 0 0 6 (2.5) 
No = number of patients, % = percentage of the total 241 patients, *Degree of global developmental delay/intellectual disability (mental retardation): SP = severe to profound,  
MO = moderate, MI = mild, BL = borderline. #NO = no global developmental delay/intellectual disability (mental retardation), only defect in the motor or speech development  
 
  
 
Table 19. Association between categories of global  
     developmental delay/intellectual disability and  
     recognized aetiology 
 
Degree of 
disability+ 
Aetiology detected  
No 
Total 
No 
 
% 
SP+ 64 100 64.0 
MO+ 25 35 71.4 
MI+ 30 51 58.8 
BL+ 21 29 72.4 
NO# 20 26 76.9 
Total 160 241 66.4 
No = number of patients, % = percentage of patients in each category,  
+Degree of global developmental delay/intellectual disability (mental retardation):  
SP = severe to profound, MO = moderate, MI = mild, BL = borderline,  
#NO = no global developmental delay/intellectual disability (mental retardation),  
only defect in the motor or speech development 
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DISCUSSION 
 
 This retrospective study presents the results of an extensive investigation into the 
profile of neurodevelopmental disabilities in a cohort of children. We followed the recent 
concept of Shevell and patients with single domain disabilities, such as isolated motor 
defect, or developmental language disorder without intellectual disability were also 
included in the study.1,2,9 Classification of patients into two major groups based on the 
absence or presence of definite proof of prenatal, perinatal, and/or neonatal adverse events 
seems to be justified, because detailed analysis of the prenatal/perinatal/neonatal history can 
shape the direction of evaluation and has a significant role in determining the aetiology of 
neurodevelopmental disabilities.4,21,26 Applying this classification scheme aetiology was 
found in 66.4% of patients. Comparison with other data reported in the literature appears to 
be difficult as referral pattern, inclusion criteria and methodology are different in almost 
each study. The aetiological yield figures tended to be about 50-54.1%20,42 in studies, which 
enrolled patients with intellectual disability only. Analysis of a group of patients with global 
developmental delay revealed the aetiology in 53% of children without autistic features.21 A 
retrospective chart review of 60 patients with global developmental delay in the same 
institution found an aetiology in 63% of cases if autistic spectrum disorder was excluded.21 
A retrospective cohort study on global developmental delay in Turkey identified aetiology 
in 64% of patients.19 Although the latter cohort study data apply to global developmental 
delay only, they are very similar to our findings. Due to significant advances in laboratory 
testing substantial improvement in the diagnostic yield is expected in the future.  
Boys were overrepresented among children with neurodevelopmental disabilities in 
this study. Similar trend was reported in the literature.3,20,21  
 
 Subgroups without known prenatal, perinatal, and/or neonatal adverse events 
Almost seventy per cent of our patients with neurodevelopmental disability in this study did 
not have any known adverse events in the prenatal, perinatal, and/or neonatal period.  
 Genetic syndromes with recognized aetiology. Patients in this subgroup had 
chromosomal abnormalities, or syndromes due to single gene defects. In agreement with the 
literature25 the dysmorphologic examination was a key element of the diagnostic evaluation 
and it provided essential guidance which additional investigations were indicated in these 
children. A systematic review of the usefulness of various diagnostic investigations in 
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individuals with mental retardation revealed that the frequency of detected chromosomal 
aberrations was around one in every 10 investigated patients.24 We found numerical or 
structural abnormalities (including those ones, recognized only by FISH) in 7.0 per cent of 
the total patient population in this study. This figure of positive findings however grew up 
to 12.9 per cent if related to the number of patients in those 4 groups in which chromosomal 
analysis was mandatory (genetic syndromes with recognized aetiology, global 
developmental delay/intellectual disability with or without dysmorphic features, and brain 
malformations, Tables 5-8). Chromosomal structural anomalies reported in this study 
showed female predominance similarly to other observations.24  
Clinical symptoms provided the lead to FISH studies in Prader-Willi, Williams and 
DiGeorge syndromes (Table 5, Patients 6-11).43 Prader-Willi and Angelman syndromes are 
imprinting disorders. In this study Angelman syndrome was the result of a rare form of 
balanced translocation and paternal uniparental disomy involving chromosome 15 in 
association with the loss of the maternally inherited UBE3A gene.44 
 Williams syndrome was caused by deletion of the WS critical region on 
chromosome 7q11.2 including the elastin (ELN) gene as well as numerous genes believed to 
contribute to the phenotype.43,45 WAGR syndrome (Table 5, Patient 12) is a rare genetic 
disorder characterized by a de novo deletion of 11p13. PAX6 and WT1 genes reside in the 
11p13 region, the former is involved in ocular and central nervous system development, 
whereas the latter (Wilms tumour gene) is a tumour suppressor gene.46 The 10p deletion in 
HDR syndrome (Table 5, Patient 13) probably was associated with GATA3 
haploinsufficiency, which proved to be the cause of the syndrome.47 Patient 14 (Table 5) 
with ring chromosome 22 accompanied by severe intellectual disability and epilepsy 
presumably was hemizygous for the SHANK3 gene.48 The translocation in Patient 15 (Table 
5) was seemingly balanced, however involvement of genes located near the breaking point 
on chromosome 3 and responsible for atypical autism, blepharophimosis and vermis 
hypoplasia might explain the clinical symptoms.49,50 
 Fragile X syndrome (Table 5, Patient 18) arose from an expansion of triplet repeats 
in the FMR1 gene with the result of hypermethylation of the CpG islands in the promoter 
region of the gene preventing gene expression.51 Mutations in the gene encoding methyl-
CpG-binding protein 2 (MECP2), as shown in Patient 20 (Table 5), are the most common 
causes of classical Rett syndrome.52 Heterozygous mutations in TSC1 or TSC2 and NF1 
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genes cause tuberous sclerosis and neurofibromatosis type 1 (Table 5, Patients 21-23), 
respectively.53,54 Loss of TSC1 or TSC2 encoded proteins (hamartin, or tuberin) leads to 
overactivation of mammalian target of rapamycin (mTOR) and disinhibition of cell growth 
and proliferation.45 The NF1 product neurofibromin-1 is a negative regulator of Ras-kinase 
and its loss also leads to overactivation of mTOR through a sophisticated signalling process 
leading to excessive mRNA translation in both neuronal and glial cells.45 Waardenburg 
syndrome (WS1) due to PAX3 mutation (Table 5, Patient 24) is a neurocristopathy usually 
with preserved cognition;55 our patient however showed borderline  intellectual disability. 
RNA toxicity leading to severe clinical symptoms is the result of CTG repeat expansion in 
the DMPK gene in congenital myotonic dystrophy (Table 5, Patient 25).56 
 A few genes have been implicated in Cornelia de Lange syndrome,57 VACTERL 
association58 and blepharophimosis–mental retardation syndrome,59 however our cases are 
still awaiting their molecular diagnoses. 
   The cognitive and behavioural phenotype of several neurodevelopmental syndromes 
with well documented genetic bases have been reviewed by Siegel and Smith.60 Intellectual 
disability with a wide range in severity can be associated with certain syndromes (i.e. 
Down, or Fragile X syndromes), while the cognitive defect remains usually mild/moderate 
in other syndromes (i.e. Prader-Willi, Williams, DiGeorge syndromes) and in numerical 
anomalies of the sex chromosomes.24,60-62 Our results presented in Tables 5 and 17 are 
essentially in agreement with the findings described in the literature.  
  Global developmental delay/intellectual disability (mental retardation) with 
dysmorphic features not recognized as specific syndromes. Unfortunately 
dysmorphologic evaluation of children with neurodevelopmental disabilities remained 
unsuccessful in terms of syndrome recognition in almost 10% of our patients with male 
preponderance (Table 6). Routine chromosomal analysis and FMR1 gene testing failed to 
show any abnormalities. The availability of subtelomeric FISH (1 patient only) and 
chromosomal microarray (3 cases only) was highly limited so far.   
The co-occurrence of mental retardation and minor anomalies has been suggested 
long time ago.34,63 The application of the FISH technique to examine the subtelomere region 
of each chromosome led to the awareness that submicroscopic subtelomeric chromosome 
rearrangements can be a significant cause of malformation and mental retardation.64 
Submicroscopic subtelomeric chromosome defects have been found in 7.4% of children 
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with moderate to severe mental retardation and in 0.5% of children with mild retardation of 
unknown aetiology, both groups of patients with normal G banded chromosomes.25,65 
Meanwhile subtelomeric FISH has been replaced by a new technology, chromosomal 
microarray, which permits genome-wide detection of copy number variants (deletions and 
duplications) at a significantly higher resolution than G-banded karyotyping.66,67 A 2010 
consensus statement by the International Standard Cytogenetic Array Consortium indicated 
that chromosomal microarray should be the first-line diagnostic test for individuals with 
global developmental delay or intellectual disability, autism spectrum disorders, or multiple 
congenital anomalies.66 As a next step in the diagnostic work up whole-exome sequencing 
should be considered for the array negative cases.67,68 According to these guidelines all 
patients in this group are candidates for chromosomal microarray followed by whole-exome 
sequencing depending on the results gained by the array.67   
Global developmental delay/intellectual disability without recognized aetiology 
and dysmorphic features. Patients with non-syndromic forms of intellectual disability 
belong into this group (Table 7).  The availability of chromosomal array (in 2 cases only) 
and mutation analysis (for 3 children) was limited for these patients as well and these tests 
failed to show any abnormalities. Extensive genetic heterogeneity can be experienced in this 
type of intellectual disability. Large number of autosomal and X-linked causative genes 
have been recognized by various approaches.68 Application of new technologies, i.e. whole 
exome sequencing has made it theoretically possible to identify causal mutations in most 
individuals with intellectual impairment regardless of frequency, heterogeneity, and 
inheritance.68,69 The extensive research in the last decade provided evidence that molecular 
networks involving intellectual disability genes can be found in presynaptic pathways, 
postsynaptic protein complexes, cytoskeleton dynamics, intracellular signal transduction 
pathways, transcription regulation, epigenetic modulation of the chromatin structure and 
post-transcriptional mechanisms for controlling gene expression.45,70 Hence our patients 
with non-syndromic intellectual disability, similarly to patients with dysmorphic features in 
the previous group are candidates for being tested by new techniques. 
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Brain malformations. Brain abnormalities can often be found by brain imaging in 
patients with neurodevelopmental disabilities.24,25 With special attention only to 
malformations, 16.3% and 18% of patients with global developmental delay had cerebral 
dysgenesis as reported by Özmen et al.19 and Srour et al.21 These figures are close to the 
frequency of brain malformations in 14.5% of children with neurodevelopmental disabilities 
in this study. 
 The presence of cerebral dysgenesis explains neurodevelopmental delay,71-79 which 
proved to be severe/profound in the majority of patients in this survey. Brain malformations 
are a major cause of cerebral palsy,80 and indeed, almost one third of our cases with brain 
malformations had cerebral palsy. On the other hand 15% of all cerebral palsy cases in this 
cohort were caused by brain malformations. Brain malformations were responsible for 
cerebral palsy only in 8.6% and 11.3% of patients according to Garne et al.80 and Self et 
al.,81 respectively. The differing data probably reflect some bias in the referral system.   
Although brain malformation was regarded as aetiology in our calculations, the 
malformations themselves are the sequels of genetic defects or environmental factors.25 
Gene defects causing brain malformations and revealed in 20% of our patients, can be 
considered as real aetiologies, while the majority of cases with cerebral dysgenesis await 
recognition of their real causes. Rare copy number variants has been found recently by array 
comparative genomic hybridization in cerebral dysgenesis82 and whole-exome sequencing 
has also been successful in identifying mutations responsible for brain malformations.83 
Application of these new technologies in our cases with unknown aetiology is under way. 
 Schizencephaly was found as the second most common malformation in this survey 
after corpus callosum anomalies. It has been suggested by a recent study that important non-
genetic factors, such as young maternal age, lack of prenatal care and alcohol use can be 
significantly associated with risk of schizencephaly.84 Indeed; the aetiological role of 
environmental factors should be considered, however difficult it is in a retrospective study. 
Inborn errors of metabolism. Neonatal screening programme for metabolic 
disorders identify children with several treatable inborn errors of metabolism in Hungary. 
There are however metabolic disorders, like Lesch-Nyhan syndrome or mitochondrial 
diseases, found in this study, which escape the diagnosis by routine neonatal screening. 
 Overall the yield of metabolic studies is low in patients with neurodevelopmental 
disabilities. Van Karnebeek et al. reported in their review that the positive results varied 
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from 0.2 to 8.4% (median 1.0%) among patients with mental retardation; the higher figures 
were from countries where specific entities were more common, or the population was 
highly inbred.24 Unselected metabolic screening provides extremely low yield hence the 
metabolic tests should be targeted at the suspected category of disorders.25 The family 
history in Lesch-Nyhan syndrome and the clinical features/MRI abnormalities in 
mitochondrial diseases provided the clue to the correct diagnosis in our cases. The 
frequency of metabolic disorders among children with global developmental delay was 
reported by Özmen et al. and Srour et al. as 4% and 2%, respectively,19,21 which figures are 
in a good agreement with the result of 2.5% in this survey. 
 The gender distribution was strongly shifted towards the male sex in this group. The 
X-linked Lesch-Nyhan syndrome was found in half of the patients due to mutation in the 
HPRT gene, which encodes the purine salvage enzyme hypoxanthine-guanine 
phosphoribosyltransferase. Mental retardation and other clinical symptoms in these patients 
were similar to the findings described in the literature.85 
 Leigh syndrome is a devastating neurodegenerative disorder86 and it was caused by a 
mutation in the mitochondrial DNA in our patient. Mitochondrial DNA deletions were 
responsible for Kearns-Sayre syndrome in two patients. Cognitive dysfunction was 
observed in addition to ataxia, visual and hearing impairment in these patients similarly to 
features described in the literature.87 Characteristic patterns of MRI abnormalities were 
suggestive of mitochondrial disease in all 3 cases.  
Leukoencephalopathies. White matter disorders or leukoencephalopathies 
comprise all disorders that exclusively or predominantly affect the white matter of the 
brain.88 Many leukoencephalopathies are the result of inborn error of metabolism, however 
the major involvement of the white matter justifies classifying these disorders separately in 
spite of the obvious overlap with the previous group of patients with neurodevelopmental 
disorders.88 Distinct patterns of MRI abnormalities provided the clue to the diagnosis in all 
cases and molecular genetic tests confirmed the specific aetiology in 3 patients (Alexander 
disease, X-linked adrenoleukodystrophy and Krabbe disease). All patients in this series had 
cognitive disability associated with a progressive clinical course. Srour et al reported on the 
occurrence of leukodystrophy in 2% of patients in a cohort with global developmental 
delay,21 which figure is rather close to the figure of 1.6% in this study. 
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  The role of MRI in the diagnosis of neurodevelopmental disabilities is highlighted 
by our findings. It proved to be essential in the diagnosis of brain malformations and 
leukoencephalopathies and guided the investigations in certain types of inborn errors of 
metabolism. Altogether it had a fundamental diagnostic value in 42 cases, which equals 
17.4% of all patients and 25.1% of children without known adverse events or risk factors.     
Epileptic syndromes. Early onset epileptic encephalopathies such as malignant 
migrating partial seizures and West syndrome in this study, are characterized by frequent 
severe seizures, neurodevelopmental disability and usually poor outcome.89,90 Risk factors 
or adverse events were not found in the history of our patients and the MRI was normal at 
the beginning of the seizures. Causative mutations in several genes have been identified 
recently in both syndromes,89,90 however molecular genetic tests were not available for our 
patients.  
 Early onset epileptic encephalopathies with unknown aetiology as causes of global 
developmental delay have not been mentioned in earlier cohort studies,19,21 hence 
comparison was not feasible.  
Developmental (specific) language impairment. In developmental (specific) 
language impairment predominantly a single developmental domain is affected, although 
longitudinal studies provided evidence that the delay may not be solely restricted to the 
language domain over time.1,91 This disorder is supposed to be the result of an interplay 
between genetic, environmental, neurobiological and cognitive (perception, speed of 
processing, working memory and phonological short-term memory) factors.91,92 
Developmental language impairment is a heterogeneous disorder with various subgroups 
and a changing profile for each individual across development.91 
The prevalence of specific language impairment was estimated as 7.4% among 
kindergarten children in the USA.93 Only 0.5% of the total 1764 patients referred to our 
Paediatric Neurology Service had developmental language impairment and it occurred only 
in 3.7% of the children with neurodevelopmental disabilities. Obviously most of the 
children with this impairment were referred to speech therapist and escaped registration by 
us. All patients in our cohort were boys and the aetiology of the disorder remained 
unknown. Almost half of them had borderline intellectual abilities. These findings were in 
agreement with data in the literature.91  
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Neuromuscular disorders. Gross motor delay and/or decline with or without 
cognitive impairment are the main clinical features of neuromuscular disorders and these 
genetic diseases constitute an important group of neurodevelopmental disabilities. Data on 
the prevalence of neuromuscular disorders among children with global developmental delay 
were not available for comparison.19,21 All patients in our study showed motor disability as 
described in the literature94 and the diagnosis was confirmed by molecular testing in all 
cases, except a patient with nemaline and another one with centronuclear myopathy (Table 
13). A review has been published on the cognition in neuromuscular disorders by 
D’Angelo95 and our experiences were in good agreement with the findings summarized by 
this publication. There was no cognitive impairment in spinal muscular atrophy, congenital 
myasthenia,96 centronuclear myopathy and one of the patients with nemaline myopathy. 
Mild or moderate intellectual disability was found in another case with nemaline 
myopathy,97 Duchenne muscular dystrophy and facioscapulohumeral dystrophy. The patient 
with congenital myotubular myopathy had very severe intellectual disability in addition to 
ventilator dependency, as described in the literature.98 A high correlation has been found 
between cognitive features and cerebral protein expression in Duchenne muscular 
dystrophy.95 It has been proven recently that intelligence quotient is related to the D4Z4 
repeat number in facioscapulohumeral dystrophy.99 Correlation between tissue-specific 
protein expression and cognitive deficits, however, is still elusive in congenital 
myopathies.95  
 
Subgroups with known prenatal, perinatal, and/or neonatal adverse events  
 Cerebral palsy due to known adverse events and including patients after preterm, or 
term delivery was the most common form of neurodevelopmental disability in this study, 
affecting 23.2 % of the patients altogether. Cerebral palsy occurred in association with brain 
malformations as well in 4.2 % of the total population of the cohort, since the total rate of 
cerebral palsy was 27.4%. These figures are in agreement with literature data, which claim 
that cerebral palsy is the commonest cause of physical disability in childhood.100 Based on 
the differing risk factors and pathophysiology it was justified to classify patients with 
cerebral palsy into two groups depending on the gestational age at birth.      
Cerebral palsy after preterm delivery. Cerebral palsy prevalence increases with 
lower birth weight and higher immaturity.100 Typical periventricular lesions were found in 
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our patients, which were „complex amalgam of destructive and developmental 
disturbances” as reviewed by Khwaja and Volpe.101,102 According to the population based 
Surveillance of Cerebral Palsy in Europe around half of the children with cerebral palsy 
were born at term, 20% had a gestational age of 32-36 weeks and 25% were below 32 
weeks of gestation between 1977-1996.100,103 In contrast to these European data recorded 
earlier, our cohort study showed that 45.5% of the total 66 cerebral palsy cases (preterm, 
term after adverse events plus patients with brain malformations, all term) was born at term, 
54.5% was preterm, only 9% had a gestational age of 32-36 weeks and 43.9% of them were 
born at or below 32 weeks of gestation. These data emphasize the risk that the high preterm 
delivery rate in Hungary means, although some bias in the referrals might have influenced 
the data in this cohort study.  
A male excess of cerebral palsy among preterm infants has been reported104 and sex 
differences in cell death pathways in the foetal or neonatal period have been suggested.105 
There were more boys in our cohort as well, however the male preponderance was 
statistically not significant. 
There are controversial data on the prevalence of cerebral palsy among preterm 
twins.106 In our cohort almost one third of the preterm infants developing cerebral palsy 
later, were products of twin pregnancy suggesting that twinning was a risk factor in this 
population. Assisted conception occurred only in a single case (Table 14, Patient 4) among 
these twins. Neurodevelopmental disability, including cerebral palsy is more common in 
infants with intrauterine growth retardation.107 Both patients in this study (Table 14, 
Patients 5 and 6) had spastic quadriplegia and severe intellectual disability. Intrauterine 
CMV infection is a well-known aetiology of cerebral palsy,108 the preterm infant (Table 14, 
Patient 3) in this study also had very severe spastic quadriplegia in addition to visual and 
hearing impairment, epilepsy and intellectual disability.  Although the majority of preterm 
infants with cerebral palsy had severe intellectual disability as well, almost one fifth of them 
showed borderline and another fifth normal intellect.       
Cerebral palsy after delivery at term. Ten risk factors have been identified 
recently for cerebral palsy in children born at term: placental abnormalities, major and 
minor birth defects, low birth weight, meconium aspiration, instrumental/emergency 
Caesarean delivery, birth asphyxia, neonatal seizures, respiratory distress syndrome, 
hypoglycaemia, and neonatal infections.109 The underlying pathology generally seems to be 
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different in patients with cerebral palsy born at term than in children born preterm. 
Malformations, cortical and deep grey matter lesions and infarct (stroke) are more common 
in term born cerebral palsy cases.100  
The spectrum of risk factors and pathologies in our patients with cerebral palsy after 
delivery at term is in agreement with literature data. Intrapartum asphyxia was the most 
common aetiology followed by intrauterine growth retardation due to placental 
abnormalities and infections. Neonatal stroke was diagnosed following intrapartum 
asphyxia in a case (Table 15, Patient 18), while the aetiology of stroke remained unknown 
in 2 children (Table 15, Patients 15, 16). As discussed earlier 10 patients with brain 
malformations, all born at term, had cerebral palsy (Table 8). A genetic cause was identified 
in the patient with lissencephaly (Table 8, Patient 18), while a genetic cause, not identified 
yet,  is very likely in another patient with pontocerebellar hypoplasia (Table 8, Patient 34). 
In the other 8 cases with polymicrogyria and/or schizencephaly the aetiology might be 
environmental or genetic. 
The intellectual disability was severe in the majority of patients with cerebral palsy 
born at term, however the intellectual performance remained normal based on our testing in 
almost one third of the patients.  
Neurodevelopmental disabilities subsequent known prenatal, perinatal, and/or 
neonatal adverse events but without cerebral palsy. There were patients in our cohort, 
born preterm or at term, who were exposed to some adverse events however did not have 
cerebral palsy. This was a heterogeneous group of children, all of them with intellectual 
disability without major motor defect. The risk factors and pathophysiology of cerebral 
injury very likely showed the same pattern as in patients with cerebral palsy discussed 
above. 
 
Limitations 
 This was a retrospective study; therefore, some of the limitations of retrospective 
studies, such as incomplete data assessment, apply.  
Our sample represents a cohort of children with neurodevelopmental disabilities 
referred to subspecialty evaluation to a Paediatric Neurology Service, therefore the results 
may not generalize to other populations where medical practice, expertise, referral patterns, 
accessibility to medical care may be different.  
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Although age specific developmental and intelligence tests were performed for  
large number of children at our Department, the majority of patients were tested by the 
Committees for the Assessment of Learning Abilities and Rehabilitation responsible for 
children’s evaluation in Hungary. 
There are also limitations as to the intensity of diagnostic workup. For example, only 
few patients underwent subtelomeric chromosomal rearrangement, or aCGH screening 
because of financial limitations. It applies also to gene tests and next generation sequencing. 
If these methods were employed more commonly during the routine workup, we would 
anticipate a higher etiologic yield than that obtained. 
 
Conclusions 
 This study provides data on the distribution of the various diagnostic categories of 
neurodevelopmental disabilities in a cohort of patients referred to a Paediatric Neurology 
Service in Hungary. The degree of global developmental delay/intellectual disability has 
been assessed in each group. Aetiology was found in 66.4% of patients, which compares 
with data in the literature. Recognition of the causes of neurodevelopmental disabilities 
helps starting adequate treatment, when feasible and establishing a health maintenance plan 
and rehabilitation. It provides prediction of the outcome, helps in avoiding unnecessary 
diagnostic tests and contributes to the prevention of the recurrence of the disorder.         
 A manageable database has been set up, which can be used for further studies on the 
genetic and environmental causes of neurodevelopmental disorders. This database provides 
useful information for the public health authorities as well on the special needs of children 
living with neurodevelopmental disabilities. 
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